New York, Jan 15, 2026, 11:16 EST — Regular session.
- Pfizer shares edge lower in regular trading as vaccine makers confront fresh policy uncertainty in the United States.
- Sanofi flagged near-term softness in U.S. vaccine demand; Pfizer’s CEO criticised the shift in recommendations.
- Investors are looking to Pfizer’s Feb. 3 results for an updated read on 2026 pressure points and pipeline priorities.
Pfizer Inc. shares fell 0.6% to $25.42 in late-morning trading on Thursday, extending a choppy start to the year for the drugmaker’s stock.
The stock has struggled to find a clear driver since Pfizer warned in December that 2026 would likely start “bumpy,” with lower COVID-related sales, price cuts tied to a U.S. government deal and key patent expirations looming. Loss of exclusivity is shorthand for patents ending, which can open the door to cheaper rivals. (Reuters)
The political noise around vaccines is back in focus. Sanofi Chief Executive Paul Hudson said the company was bracing for weaker U.S. vaccine demand this year and told reporters: “We expected some softness.” Pfizer CEO Albert Bourla struck a harder tone, saying, “What is happening has zero scientific merit and is just serving an agenda which is political and antivax,” after U.S. officials changed the childhood vaccine schedule and shifted some shots into high-risk or shared decision-making categories. (Reuters)
Other vaccine-linked names were lower too. Moderna fell 1.9% and Merck slipped 0.9% in late morning trading.
Pfizer also sits in the middle of a scramble for the next growth story: obesity drugs. Structure Therapeutics CEO Raymond Stevens told Reuters that oral GLP-1 weight-loss pills could capture up to half the market by 2030 as prescriptions spread beyond specialists, adding, “that’s where we’re really going to see the most growth occurring.” GLP-1, short for glucagon-like peptide-1, is the hormone pathway targeted by blockbuster obesity and diabetes drugs, currently led by Novo Nordisk and Eli Lilly. Pfizer bought Metsera for $10 billion last November to gain a foothold in that race. (Reuters)
For Pfizer, the market’s question is simple and stubborn: can new products and deal-making offset fading pandemic-era revenue and the next wave of patent losses without blowing out costs.
The next hard catalyst is Feb. 3, when Pfizer is scheduled to host its quarterly corporate performance update for fourth-quarter and full-year 2025 results. (Pfizer)
But the downside case has not gone away. A sharper drop in vaccination rates would hit an already pressured respiratory franchise, and Washington-driven uncertainty can change demand assumptions faster than drugmakers can adjust supply and spending.
Traders will watch for any further U.S. moves on vaccine recommendations, but the immediate trigger for Pfizer stock is what management says on Feb. 3 about the 2026 outlook and how quickly the pipeline can start carrying the load.
